LUKAS C. AMLER,MERRILL BIRKNER,CHIN-YU LIN,JOACHIM MOECKS,ANDREAS STRAUSS
申请号：
BRPI0808418
公开号：
BRPI0808418A2
申请日:
2008.02.29
申请国别(地区):
BR
年份:
2014
代理人:
摘要：
The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
